THE US EARLY-STAGE BIOTECH VC WORLD MAY HAVE COMPLETED ITS SHAKEOUT, resulting in just a handful of of real companies still active. This concentration of a smaller pot of capital among fewer firms will make all the earlier predictions true: competition for capital will increase. Further, there is the possibility that these remaining funds may be more creative and less arrogant than their predecessors.
http://lnkd.in/_8k26V
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022